Download PDF
Semin Neurol 2017; 37(06): 611-623
DOI: 10.1055/s-0037-1608932
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Delivery of a Personalized Treatment Approach to Women with Epilepsy

P. Emanuela Voinescu
1   Department of Neurology, Harvard Medical School, Boston, Massachusetts
2   Division of Epilepsy, Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115
,
Page B. Pennell
1   Department of Neurology, Harvard Medical School, Boston, Massachusetts
2   Division of Epilepsy, Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2017 (online)

    Permissions and Reprints

Abstract

Personalized treatment for women with epilepsy is essential, and requires thorough weighing of the risks and benefits of the initial diagnostic and therapeutic options chosen, with readjustments of the antiepileptic regimen throughout the patient's life.

Approximately one-third of women with epilepsy have a catamenial pattern, and the most common pattern is an increase in seizure frequency in the perimenstrual phase. These women are also more likely to experience a decrease in seizure frequency during pregnancy and menopause. A good treatment option for catamenial epilepsy is still lacking.

For contraception, an intrauterine device is currently the preferred choice. Prior to conception, it is advisable to review the known impact of different antiepileptic drugs on the developing fetus and to optimize the patient's treatment regimen. Pregnancy registries and observational studies have provided key data and continue to refine our understanding of the risks to the structural and cognitive development of the fetus of specific antiepileptic drugs, including polytherapies and newer medications. Different studies consistently report that valproic acid has notably high relative risks for congenital malformations, lower IQ, and features of autism. During pregnancy, there is growing evidence that therapeutic dose monitoring is beneficial for seizure control. Counseling about seizure safety and minimizing provoking factors during the peripartum period is important for the patient with epilepsy.

Clinical studies continue to investigate the complex relationship between cycling sex steroid hormones, epilepsy, and antiepileptic medications, with hopes to better explain drug clearance changes during pregnancy, changes in seizure frequency, and neuroendocrine abnormalities. Thorough understanding of these key factors and a continuous review of literature for updated data on different treatment options will enable optimal treatment recommendations that will improve the health of women with epilepsy and their children.

Keywords

epilepsy - women's neurology - women's health - antiepileptic drugs - catamenial epilepsy - contraception - pregnancy - therapeutic drug monitoring - menopause - breastfeeding
 

  • References

  • 1 Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38 (10) 1082-1088
    CrossrefPubMedGoogle Scholar
  • 2 Pennell PB. Pregnancy, epilepsy, and women's issues. Continuum (Minneap Minn) 2013; 19 (3 Epilepsy): 697-714
    PubMedGoogle Scholar
  • 3 Herzog AG, Fowler KM, Smithson SD. , et al; Progesterone Trial Study Group. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology 2012; 78 (24) 1959-1966
    CrossrefPubMedGoogle Scholar
  • 4 Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984; 34 (09) 1255-1258
    CrossrefPubMedGoogle Scholar
  • 5 Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001; 42 (06) 746-749
    CrossrefPubMedGoogle Scholar
  • 6 Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet 1982; 2 (8289): 71-73
    PubMedGoogle Scholar
  • 7 Pylvänen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojärvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43 (05) 514-517
    CrossrefPubMedGoogle Scholar
  • 8 Morrell MJ, Hayes FJ, Sluss PM. , et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64 (02) 200-211
    CrossrefPubMedGoogle Scholar
  • 9 French J, Harden C, Pennell P. , et al. A Prospective Study of Pregnancy in Women with Epilepsy Seeking Conception (The WEPOD Study)(I5. 001). Neurology 2016; 86 (16) I5.001
    PubMedGoogle Scholar
  • 10 Morrell MJ, Flynn KL, Doñe S, Flaster E, Kalayjian L, Pack AM. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 2005; 6 (03) 360-365
    CrossrefPubMedGoogle Scholar
  • 11 Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia 2001; 42 (12) 1584-1589
    PubMedGoogle Scholar
  • 12 Harden CL, Koppel BS, Herzog AG, Nikolov BG, Hauser WA. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology 2003; 61 (04) 451-455
    CrossrefPubMedGoogle Scholar
  • 13 Harden CL, Herzog AG, Nikolov BG. , et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47 (09) 1447-1451
    CrossrefPubMedGoogle Scholar
  • 14 Sveinsson O, Tomson T. Epilepsy and menopause: potential implications for pharmacotherapy. Drugs Aging 2014; 31 (09) 671-675
    CrossrefPubMedGoogle Scholar
  • 15 Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999; 40 (10) 1402-1407
    CrossrefPubMedGoogle Scholar
  • 16 Fabris RR, Cascino TG, Mandrekar J, Marsh WR, Meyer FB, Cascino GD. Drug-resistant focal epilepsy in women of childbearing age: reproduction and the effect of epilepsy surgery. Epilepsy Behav 2016; 60: 17-20
    CrossrefPubMedGoogle Scholar
  • 17 American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 656: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol 2016; 127 (02) e75-e80
    CrossrefPubMedGoogle Scholar
  • 18 Harden CL, Meador KJ, Pennell PB. , et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73 (02) 133-141
    CrossrefPubMedGoogle Scholar
  • 19 Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51 (05) 805-810
    CrossrefPubMedGoogle Scholar
  • 20 Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68 (10) 1275-1281
    CrossrefPubMedGoogle Scholar
  • 21 Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ. The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014; 130 (04) 234-238
    CrossrefPubMedGoogle Scholar
  • 22 Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014; 261 (03) 579-588
    CrossrefPubMedGoogle Scholar
  • 23 Voinescu PE, Pennell PB. Management of epilepsy during pregnancy. Expert Rev Neurother 2015; 15 (10) 1171-1187
    CrossrefPubMedGoogle Scholar
  • 24 Tomson T, Battino D, Bonizzoni E. , et al; EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10 (07) 609-617
    CrossrefPubMedGoogle Scholar
  • 25 Campbell E, Devenney E, Morrow J. , et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero. Epilepsia 2013; 54 (01) 165-171
    CrossrefPubMedGoogle Scholar
  • 26 Vajda FJ, O'Brien TJ, Lander CM, Graham J, Roten A, Eadie MJ. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013; 54 (01) 181-186
    CrossrefPubMedGoogle Scholar
  • 27 Harden CL, Pennell PB, Koppel BS. , et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73 (02) 142-149
    CrossrefPubMedGoogle Scholar
  • 28 Valera-Gran D, García de la Hera M, Navarrete-Muñoz EM. , et al; Infancia y Medio Ambiente (INMA) Project. Folic acid supplements during pregnancy and child psychomotor development after the first year of life. JAMA Pediatr 2014; 168 (11) e142611
    CrossrefPubMedGoogle Scholar
  • 29 Meador KJ, Baker GA, Browning N. , et al; NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 2013; 12 (03) 244-252
    CrossrefPubMedGoogle Scholar
  • 30 Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology 2014; 83 (04) 339-344
    CrossrefPubMedGoogle Scholar
  • 31 Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia 2014; 55 (07) e72-e74
    CrossrefPubMedGoogle Scholar
  • 32 Harden CL, Hopp J, Ting TY. , et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73 (02) 126-132
    CrossrefPubMedGoogle Scholar
  • 33 La Neve A, Boero G, Francavilla T, Plantamura M, De Agazio G, Specchio LM. Prospective, case-control study on the effect of pregnancy on seizure frequency in women with epilepsy. Neurol Sci 2015; 36 (01) 79-83
    PubMedGoogle Scholar
  • 34 Battino D, Tomson T, Bonizzoni E. , et al; EURAP Study Group. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013; 54 (09) 1621-1627
    CrossrefPubMedGoogle Scholar
  • 35 Thomas SV, Syam U, Devi JS. Predictors of seizures during pregnancy in women with epilepsy. Epilepsia 2012; 53 (05) e85-e88
    CrossrefPubMedGoogle Scholar
  • 36 Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7 (01) 3-6
    CrossrefPubMedGoogle Scholar
  • 37 Adab N, Kini U, Vinten J. , et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75 (11) 1575-1583
    CrossrefPubMedGoogle Scholar
  • 38 Baker GA, Bromley RL, Briggs M. , et al; Liverpool and Manchester Neurodevelopment Group. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84 (04) 382-390
    CrossrefPubMedGoogle Scholar
  • 39 Chen Y-H, Chiou H-Y, Lin H-C, Lin H-L. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 2009; 66 (08) 979-984
    PubMedGoogle Scholar
  • 40 Hernández-Díaz S, Smith CR, Shen A. , et al; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78 (21) 1692-1699
    CrossrefPubMedGoogle Scholar
  • 41 Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11 (09) 803-813
    CrossrefPubMedGoogle Scholar
  • 42 Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure 2015; 28: 46-50
    CrossrefPubMedGoogle Scholar
  • 43 Veroniki AA, Cogo E, Rios P. , et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 2017; 15 (01) 95
    CrossrefPubMedGoogle Scholar
  • 44 Meador KJ, Baker GA, Browning N. , et al; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360 (16) 1597-1605
    CrossrefPubMedGoogle Scholar
  • 45 Meador KJ, Baker GA, Browning N. , et al; NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 2012; 78 (16) 1207-1214
    CrossrefPubMedGoogle Scholar
  • 46 Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA. ; Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76 (04) 383-389
    CrossrefPubMedGoogle Scholar
  • 47 Bromley RL, Calderbank R, Cheyne CP. , et al; UK Epilepsy and Pregnancy Register. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 2016; 87 (18) 1943-1953
    CrossrefPubMedGoogle Scholar
  • 48 Shallcross R, Bromley RL, Cheyne CP. , et al; Liverpool and Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 2014; 82 (03) 213-221
    CrossrefPubMedGoogle Scholar
  • 49 Bromley RL, Mawer GE, Briggs M. , et al; Liverpool and Manchester Neurodevelopment Group. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013; 84 (06) 637-643
    CrossrefPubMedGoogle Scholar
  • 50 Bromley R, Weston J, Adab N. , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014; (10) CD010236
    PubMedGoogle Scholar
  • 51 Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274 (19) 1518-1525
    CrossrefPubMedGoogle Scholar
  • 52 Christensen J, Grønborg TK, Sørensen MJ. , et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309 (16) 1696-1703
    CrossrefPubMedGoogle Scholar
  • 53 Kilic D, Pedersen H, Kjaersgaard MI. , et al. Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014; 55 (11) 1714-1721
    CrossrefPubMedGoogle Scholar
  • 54 Artama M, Gissler M, Malm H, Ritvanen A. ; Drug and Pregnancy Group. Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 2013; 36 (05) 359-369
    CrossrefPubMedGoogle Scholar
  • 55 Razaz N, Tomson T, Wikström A-K, Cnattingius S. Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy. JAMA Neurol 2017; 74 (08) 983-991
    CrossrefPubMedGoogle Scholar
  • 56 Hernández-Díaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB. ; North American Antiepileptic Drug Pregnancy Registry. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014; 123 (01) 21-28
    CrossrefPubMedGoogle Scholar
  • 57 Pennell PB, Klein AM, Browning N. , et al; NEAD Study Group. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav 2012; 24 (04) 449-456
    CrossrefPubMedGoogle Scholar
  • 58 MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurol 2015; 72 (09) 981-988
    CrossrefPubMedGoogle Scholar
  • 59 Pennell PB, Peng L, Newport DJ. , et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70 (22 Pt 2): 2130-2136
    CrossrefPubMedGoogle Scholar
  • 60 Johnson EL, Stowe ZN, Ritchie JC. , et al. Carbamazepine clearance and seizure stability during pregnancy. Epilepsy Behav 2014; 33: 49-53
    CrossrefPubMedGoogle Scholar
  • 61 Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav 2013; 29 (01) 13-18
    CrossrefPubMedGoogle Scholar
  • 62 Callisto S, Bathena SP, Pennell PB. , et al. Clearance changes of lamotrigine during pregnancy are detectable within the first trimester of pregnancy. AES 2016; 1.213
    PubMedGoogle Scholar
  • 63 Pirie DA, Al Wattar BH, Pirie AM. , et al. Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 172: 26-31 http://www.sciencedirect.com/science/article/pii/S030121151300540X
    CrossrefPubMedGoogle Scholar
  • 64 Meador KJ, Baker GA, Browning N. , et al; Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 2014; 168 (08) 729-736
    CrossrefPubMedGoogle Scholar